Welcome to the international HTA database

Showing [16732 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2015	NIHR Health Services and Delivery Research programme	What is the evidence on interventions to manage referral from primary to specialist non-emergency care? A systematic review and logic model synthesis
2015	NIHR Health Technology Assessment programme	The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical activity for smoking cessation in pregnancy with an economic evaluation
2015	HAYES, Inc.	Zio patch (iRhythm Technologies Inc.) for long-term ambulatory cardiac rhythm monitoring
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Buparlisib in combination with fulvestrant for hormone-receptor positive/HER2-negative locally advanced or metastatic breast cancer
2015	NIHR Health Technology Assessment programme	Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock
2015	NIHR Health Services and Delivery Research programme	Translation into British Sign Language and validation of the Strengths and Difficulties Questionnaire
2015	NIHR Health Services and Delivery Research programme	Delivering the aims of the Collaborations for Leadership in Applied Health Research and Care: understanding their strategies and contributions
2015	Agency for Healthcare Research and Quality (AHRQ)	Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force
2015	HAYES, Inc.	CancerTYPE ID
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Cabozantinib (Cometriq) for metastatic renal cell carcinoma –second line
2015	NIHR Health Technology Assessment programme	Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure
2015	NIHR Health Services and Delivery Research programme	Evaluating a major innovation in hospital design: workforce implications and impact on patient and staff experiences of all single room hospital accommodation
2015	Agency for Healthcare Research and Quality (AHRQ)	Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force
2015	HAYES, Inc.	ConfirmMDx for prostate cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Elotuzumab with lenalidomide for multiple myeloma – first line
2015	NIHR Health Technology Assessment programme	The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical activity for smoking cessation in pregnancy with an economic evaluation
2015	NIHR Health Services and Delivery Research programme	Improving practice in safeguarding at the interface between hospital services and children's social care: a mixed-methods case study
2015	Agency for Healthcare Research and Quality (AHRQ)	Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force
2015	HAYES, Inc.	know error DNA Specimen Provenance Assay (Strand Diagnostics)
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Neratinib with capecitabine for advanced or metastatic HER2-positive breast cancer – third line
2015	NIHR Health Services and Delivery Research programme	Improving community health networks for people with severe mental illness: a case study investigation
2015	Belgian Health Care Knowledge Centre (KCE)	What are the recommended clinical assessment and screening tests during pregnancy?
2015	Agency for Healthcare Research and Quality (AHRQ)	Aspirin use to prevent cardiovascular disease and cancer: a decision analysis
2015	HAYES, Inc.	Oncotype DX Colon Cancer Assay
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Palbociclib for advanced or metastatic, oestrogen-receptor positive, HER2-negative, recurrent breast cancer – second line
2015	Belgian Health Care Knowledge Centre (KCE)	Bladder cancer: an assessment of international practice guidelines
2015	Agency for Healthcare Research and Quality (AHRQ)	Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force
2015	HAYES, Inc.	Prosigna Breast Cancer Prognostic Gene Signature Assay
2015	Belgian Health Care Knowledge Centre (KCE)	Comprehensive geriatric care in hospitals: the role of inpatient geriatric consultation teams
2015	Agency for Healthcare Research and Quality (AHRQ)	Psychosocial and pharmacologic interventions for disruptive behavior in children and adolescents
2015	HAYES, Inc.	Tissue of Origin Test (ResponseDX)
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2015	Belgian Health Care Knowledge Centre (KCE)	Oncogenetic testing for persons with hereditary endocrine cancer syndromes
2015	Agency for Healthcare Research and Quality (AHRQ)	Behavioral programs for diabetes mellitus
2015	HAYES, Inc.	Autologous stem cell therapy for treatment of avascular necrosis of the hip
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Vemurafenib (Zelboraf) for metastatic BRAF V600 mutation positive melanoma in children and adolescents
2015	Belgian Health Care Knowledge Centre (KCE)	Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2.
2015	Agency for Healthcare Research and Quality (AHRQ)	Screening for speech and language delays and disorders in children age 5 years or younger: a systematic review for the U.S. Preventive Services Task Force
2015	HAYES, Inc.	Cryoablation for treatment of non-small cell lung cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	GS-6615 for long QT-3 syndrome
2015	Belgian Health Care Knowledge Centre (KCE)	Gene expression profiling and immunohistochemistry tests for personalised management of adjuvant chemotherapy decisions in early breast cancer – a Rapid Assessment
2015	HAYES, Inc.	Full-field digital mammography for breast cancer screening
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Holoclar for the treatment of limbal stem cell deficiency due to ocular burns
2015	Technology Assessment at SickKids (TASK)	A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events
2015	Belgian Health Care Knowledge Centre (KCE)	Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, LiFraumeni syndrome and Cowden syndrome
2015	Medical Services Advisory Committee (MSAC)	The use of Intensity Modulated Radiation Therapy (IMRT) in the treatment of cancer
2015	HAYES, Inc.	Intraoperative radiotherapy for treatment of early-stage breast cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Midodrine (Bramox) for orthostatic hypotension
2015	NIHR Health Technology Assessment programme	The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation
2015	Medical Services Advisory Committee (MSAC)	The use of Image Guided Radiation Therapy (IGRT) in the treatment of cancer
2015	HAYES, Inc.	Metal-on-metal hip resurfacing arthroplasty versus total hip replacement for osteoarthritis
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Tenofovir alafenamide monotherapy for hepatitis B
2015	NIHR Public Health Research (PHR) programme	Preventing domestic abuse for children and young people (PEACH): a mixed knowledge scoping review
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2015	HAYES, Inc.	MRI-TRUS fusion-guided biopsy for the diagnosis of prostate cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Baricitinib for moderate to severe rheumatoid arthritis
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rituximab (MabThera®)
2015	NIHR Health Services and Delivery Research programme	Mobilising knowledge to improve UK health care: learning from other countries and other sectors – a multimethod mapping study
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lisdexamfetamine dimesylate (Elvanse Adult®)
2015	HAYES, Inc.	K9 inhibitors for cholesterol reduction: alirocumab and bococizumab
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Certolizumab (Cimzia) for early rheumatoid arthritis – first line
2015	NIHR Health Technology Assessment programme	A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ponatinib (Iclusig®)
2015	NIHR Health Services and Delivery Research programme	Contracting with General Dental Services: a mixed-methods study on factors influencing responses to contracts in English general dental practice
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2015	HAYES, Inc.	Peroral Endoscopic Myotomy (POEM) for treatment of esophageal achalasia
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Tofacitinib for psoriatic arthritis – second or subsequent line
2015	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of telephone triage for managing same-day consultation requests in general practice: a cluster randomised controlled trial comparing general practitioner-led and nurse-led management systems with usual care (the ESTEEM trial)
2015	NIHR Health Technology Assessment programme	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Umeclidinium (Incruse®)
2015	NIHR Health Services and Delivery Research programme	The organisation and delivery of health improvement in general practice and primary care: a scoping study
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Enzalutamide (Xtandi®)
2015	HAYES, Inc.	Primary endovascular mechanical thrombectomy for treatment of acute ischemic stroke
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Patiromer for hyperkalaemia – first line
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS)
2015	Agency for Healthcare Research and Quality (AHRQ)	Treatment of nonmetastatic muscle-invasive bladder cancer
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Envarsus®)
2015	HAYES, Inc.	Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Alectinib for advanced ALK-positive, non-small cell lung cancer – first line
2015	NIHR Health Technology Assessment programme	Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Olodaterol (as hydrochloride) (Striverdi® Respimat®)
2015	Agency for Healthcare Research and Quality (AHRQ)	Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Pomalidomide (Imnovid®)
2015	HAYES, Inc.	Sonohysterography for assessment of abnormal uterine bleeding
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Alectinib for locally advanced or metastatic ALK-positive, non-small cell lung cancer following failure of crizotinib
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Cabozantinib (Cometriq®)
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Determining death in postmortal organ donation. Protocols and criteria, including an updated Brain Death Protocol
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Brimonidine (Mirvaso®)
2015	HAYES, Inc.	Spinal cord stimulation for relief of neuropathic pain
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Atezolizumab for locally advanced or metastatic non-small cell lung cancer – second line
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Follitropin alfa (Bemfola®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Beclometasone dipropionate/formoterol fumarate (Fostair®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Magnesium aspartate dihydrate (Magnaspartate)
2015	HAYES, Inc.	Staged approach to sacral nerve stimulation for treatment of fecal incontinence
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Bavituximab for advanced non-small cell lung cancer – second line in combination with docetaxel
2015	NIHR Health Technology Assessment programme	Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation
2015	Agency for Healthcare Research and Quality (AHRQ)	Relationship between use of quality measures and improved outcomes in serious mental illness
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lurasidone (Latuda®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Brentuximab vedotin (Adcetris®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rarunavir/cobicistat (Rezolsta®)